Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
Source ↗
👁 0
💬 0
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.
Comments (0)